Naltrexone & GLP-1: Advanced Craving Control for Addiction Recovery

Disclaimer: This article is for educational purposes only and should not be taken as medical advice. Always consult your licensed healthcare provider before beginning, changing, or stopping any treatment.

Substance use disorders (SUDs) continue to affect millions worldwide, challenging clinicians to find more effective and sustainable treatments. While traditional therapies—such as behavioral counseling, group therapy, and medication-assisted treatment—remain foundational, integrative psychiatry is paving a new path.

This emerging approach combines biological, psychological, and lifestyle interventions, and now includes innovative medications like naltrexone and GLP-1 receptor agonists (such as semaglutide). These drugs target brain pathways linked to reward, craving, and self-regulation, helping patients reduce their drive to use alcohol, opioids, and even food.

Naltrexone has long been a cornerstone in addiction treatment, particularly for alcohol use disorder (AUD) and opioid use disorder (OUD). It works by blocking opioid receptors in the brain, which prevents substances like alcohol or opioids from triggering euphoric effects.

This mechanism not only reduces the “high” but also diminishes cravings and relapse rates. Studies have consistently shown that when combined with therapy, naltrexone improves treatment retention and abstinence rates (source).

In integrative psychiatry settings, naltrexone is used alongside mindfulness, nutritional therapy, and trauma-informed psychotherapy to support the whole person—mind, body, and neurochemistry.

GLP-1 receptor agonists—medications like semaglutide (Ozempic®, Wegovy®)—were originally developed to manage type 2 diabetes and obesity. However, recent research suggests they may also reduce cravings for alcohol and other addictive substances by influencing the dopamine reward system in the brain.

Early studies show that GLP-1 medications can lower alcohol intake, decrease food cravings, and improve impulse control.
A 2025 JAMA Psychiatry clinical trial found that adults with alcohol use disorder taking weekly semaglutide experienced significant reductions in alcohol cravings and consumption compared to placebo (source).

For integrative psychiatrists, this represents a major leap forward—linking metabolic health with mental health in a way that’s both scientifically grounded and clinically innovative.

For an in-depth review of GLP-1 mechanisms in addiction, see The Role of Glucagon-Like Peptide 1 (GLP-1) in Alcohol and Substance Use Disorders (source).

Integrative psychiatry practices aim to treat the underlying biological and psychological causes of addiction, not just the symptoms. In this context, medications like naltrexone and GLP-1 receptor agonists are not “quick fixes” but supportive tools used within comprehensive treatment plans.

These plans often include:

The goal is to reduce cravings, enhance emotional regulation, and improve overall functioning, allowing individuals to sustain recovery more effectively.

As with any prescription medication, naltrexone and GLP-1 drugs may have side effects.

Patients should discuss these risks with their healthcare provider to make fully informed decisions. Ongoing monitoring and collaboration between psychiatrist and patient are crucial for safety and success.

The integration of naltrexone and GLP-1 therapies into addiction medicine signals a paradigm shift. Instead of viewing cravings purely as psychological, clinicians are addressing the biochemical and neuroendocrine drivers that sustain addiction.

As more evidence accumulates, integrative psychiatry is likely to lead this transformation—offering patients new hope through science-based, whole-person care.

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial (JAMA Psychiatry, 2025)

The Role of Glucagon-Like Peptide 1 (GLP-1) in Alcohol and Substance Use Disorders